Shinpoong Pharmaceutical has announced plans for a significant R&D investment, focusing on a Phase 3 clinical trial for its stroke treatment, SP-8203 (Otaprimastat), targeting 852 patients. 

The trial is expected to commence by the end of the year, requiring hundreds of billions of won for completion.

SP-8203 is a first-in-class drug candidate for stroke, aiming to improve outcomes when used alongside the current standard thrombolytic therapy, tPA. 

The drug is expected to reduce the side effects of tPA, including mortality, which will be the focus of this trial.

Over the past five years, Shinpoong Pharmaceutical has invested approximately 170.7 billion KRW in R&D, following its large block deal in 2020, despite initial skepticism from the market. 

The company has steadily increased its research spending, including major investments in its pipeline, with a particular focus on this new stroke treatment.

Industry insiders interpret these moves as a clear indication of the company's commitment to R&D, even amidst financial challenges.